UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 810

Sortiert nach

Toward personalized treatment approaches for non-small-cell lung cancer

Nature medicine, 2021-08, Vol.27 (8), p.1345-1356

2021

Link zum Volltext

Verfügbarkeit prüfen

Lung cancer in the era of precision medicine

Clinical cancer research, 2015-05, Vol.21 (10), p.2213-2220

2015

Link zum Volltext

Verfügbarkeit prüfen

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Nature reviews. Clinical oncology, 2021-10, Vol.18 (10), p.625-644

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Clinical cancer research, 2019-08, Vol.25 (15), p.4592-4602

2019

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer

Clinical cancer research, 2016-08, Vol.22 (15), p.3713-3717

2016

Link zum Volltext

Verfügbarkeit prüfen

To kill a tumor cell: the potential of proapoptotic receptor agonists

The Journal of clinical investigation, 2008-06, Vol.118 (6), p.1979-1990

2008

Link zum Volltext

Verfügbarkeit prüfen

Objective measurement and clinical significance of TILs in non-small cell lung cancer

JNCI : Journal of the National Cancer Institute, 2015-03, Vol.107 (3), p.1

2015

Link zum Volltext

Verfügbarkeit prüfen

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Clinical cancer research, 2018-04, Vol.24 (8), p.1872-1880

2018

Link zum Volltext

Verfügbarkeit prüfen

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Nature (London), 2014-11, Vol.515 (7528), p.563-567

2014

Link zum Volltext

Verfügbarkeit prüfen

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

The Lancet (British edition), 2016-04, Vol.387 (10027), p.1540-1550

2016

Link zum Volltext

Verfügbarkeit prüfen

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer

Clinical cancer research, 2018-04, Vol.24 (7), p.1562-1573

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2011, Vol.377 (9780), p.1846-1854

2011

Link zum Volltext

Verfügbarkeit prüfen

The biology and management of non-small cell lung cancer

Nature (London), 2018-01, Vol.553 (7689), p.446-454

2018

Link zum Volltext

Verfügbarkeit prüfen

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer

Clinical cancer research, 2014-08, Vol.20 (15), p.3921-3930

2014

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Link zum Volltext

Verfügbarkeit prüfen

Immuno-thermal ablations - boosting the anticancer immune response

Journal for Immunotherapy of Cancer, 2017-10, Vol.5 (1), p.78-78, Article 78

2017

Link zum Volltext

Verfügbarkeit prüfen

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Journal of thoracic oncology, 2022-03, Vol.17 (3), p.423-433

2022

Link zum Volltext

Verfügbarkeit prüfen

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1872-1882

2021

Link zum Volltext

Verfügbarkeit prüfen

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Clinical lung cancer, 2018-07, Vol.19 (4), p.e533-e536

2018

Link zum Volltext

Verfügbarkeit prüfen

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

The Journal of clinical investigation, 2016-01, Vol.126 (1), p.169-180

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 810

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(767)
Mit Volltextzugriff
(750)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(795)
Japanisch
(105)
Chinesisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(387)
Life Sciences & Biomedicine
(363)
Humans
(357)
Oncology
(317)
Lung Neoplasms - Drug Therapy
(181)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(159)
Male
(156)
Female
(147)
Biological And Medical Sciences
(142)
Medical Sciences
(138)
Aged
(120)
Middle Aged
(118)
Tumors
(109)
Lung Cancer
(106)
Lung Neoplasms - Pathology
(97)
Adult
(96)
Antineoplastic Agents
(81)
Carcinoma, Non-Small-Cell Lung - Pathology
(78)
Pharmacology. Drug Treatments
(76)
Chemotherapy
(74)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(140)
Clinical Cancer Research
(79)
Journal Of Thoracic Oncology
(78)
Cancer Research
(57)
Clinical Lung Cancer
(35)
Seminars In Oncology
(22)
The New England Journal Of Medicine
(21)
Journal For Immunotherapy Of Cancer
(18)
Cancer
(15)
The Lancet Oncology
(14)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Toward personalized treatment approaches for non-small-cell lung cancer

Lung cancer in the era of precision medicine

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC

Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer

To kill a tumor cell: the potential of proapoptotic receptor agonists

Objective measurement and clinical significance of TILs in non-small cell lung cancer

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

The biology and management of non-small cell lung cancer

A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non-Small Cell Lung Cancer

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

An Epithelial―Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Immuno-thermal ablations - boosting the anticancer immune response

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

Suchergebnisse filtern